X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Pioz V (vildagliptin + pioglitazone) is a fixed dose combination medicine that helps control blood sugar levels. It is now approved for the treatment of type-2-diabetes mellitus.
Lead Product(s): Vildagliptin,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Pioz V
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solution for diabetes.
Lead Product(s): Sitagliptin Phosphate,Pioglitazone,Metformin
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
The grant will fund ENRICH-PLUS study, examining the safety of supplementing early Minimally Invasive Parafascicular Surgery for clot evacuation of basal ganglia intracerebral hemorrhage using NICO technologies with Takeda's Actos (pioglitazone), an FDA-approved diabetes drug.
Lead Product(s): Pioglitazone
Therapeutic Area: Neurology Product Name: Actos
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NICO Corporation
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding June 22, 2023
Details:
The agreement forms the basis for discussions on the introduction, development and commercialization of KIN001, a patented combination of two APIs, pamapimod and pioglitazone, for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in China.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: ChaoDian
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2023
Details:
KIN001 is a patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
KIN001 is an orally administered combination of pamapimod and pioglitazone. Pamapimod is a p38 MAPK inhibitor, whereas pioglitazone is a PPAR gamma activator. It is currently being developed in COVID-19, Idiopathic Pulmonary Fibrosis and wet Age-Related Macular Degeneration.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
KIN001 is combination of two APIs: pamapimod and pioglitazone. Kinarus has found that combining pamapimod with pioglitazone, leads to synergistic efficacy and increased duration of action in preclinical models of wet AMD, IPF and fibrotic and inflammatory diseases.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
KIN001 is a patented combination of two active pharmaceutical ingredients (APIs): pamapimod and pioglitazone. Pamapimod is a highly selective clinical stage small molecule inhibitor of the p38 MAP kinase signaling pathway.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Great Health Companion Group Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 16, 2022
Details:
KIN001 is an orally administered combination of two drugs that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
KIN001 (pamapimod) is a proprietary novel combination of two active pharmaceutical ingredients that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis in preclinical studies.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Infections and Infectious Diseases Product Name: KIN001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
KIN001 (pamapimod) has been shown to reduce pathological blood vessel growth (neovascularization) in the choroid of the eye in preclinical models of wAMD.
Lead Product(s): Pamapimod,Pioglitazone
Therapeutic Area: Ophthalmology Product Name: KIN001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Lead Product(s): Teneligliptin Hydrobromide,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Zita Plus Pio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Lead Product(s): Alogliptin Benzoate,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Liovel
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Teijin Pharma
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 01, 2021
Details:
Results from its Phase 1b study of PXL065 and results from three preclinical studies for PXL770 will be presented as e-posters at The Liver Meeting® 2020 hosted by the American Association for the Study of Liver Diseases (AASLD).
Lead Product(s): Pioglitazone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PXL065
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Phase 2 trial will include approximately 120 noncirrhotic biopsy-proven NASH patients and is designed to identify optimal dose or doses for Phase 3 registration trial.
Lead Product(s): Pioglitazone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PXL065
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
USV offers custom peptide synthesis ranging from gram to multi-gram to multi-kilogram quantities.
